Creation of an additional glycosylation site as a mechanism for type I antithrombin deficiency

Thromb Haemost. 2001 Oct;86(4):1023-7.

Abstract

We report the identification of a new mutation resulting in type I antithrombin (AT) deficiency and the mechanism by which the deficiency arose. The single base substitution of G to A at nucleotide 2709 was identified in a proband with a family history of venous thrombosis. The mutation results in a substitution of 82 Ser by Asn, creating a new glycosylation site. Expression studies were then carried out, to confirm Asn-linked glycosylation occurred at this consensus site and that this resulted in the AT deficient phenotype. Cell-free translations using rabbit reticulocyte lysate in the presence of microsomes demonstrated that the 82 Asn variant was post-translationally processed efficiently. The 82 Asn variant protein was of a higher molecular weight than normal AT. consistent with the addition of a fifth glycan chain. Incubation of translation product with endoglycosidase H, confirmed that the higher molecular weight product had resulted from additional carbohydrate. Expression of the 82 Asn variant in COS-7 cells resulted in intracellular accumulation, with a low level of secretion of the protein into culture supernatant, consistent with type I AT deficiency. The addition of an extra carbohydrate side chain to residue 82 of antithrombin may block post-translational folding. trapping the variant intracellulary.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Amino Acid Substitution*
  • Animals
  • Antithrombin III / biosynthesis
  • Antithrombin III / genetics*
  • Antithrombin III / metabolism
  • Antithrombin III Deficiency / classification
  • Antithrombin III Deficiency / genetics*
  • COS Cells
  • Cell-Free System
  • Chlorocebus aethiops
  • Exocytosis
  • Female
  • Glycosylation
  • Humans
  • Male
  • Molecular Weight
  • Mutagenesis, Site-Directed
  • Mutation, Missense*
  • Pedigree
  • Point Mutation*
  • Protein Folding
  • Protein Processing, Post-Translational*
  • Recombinant Fusion Proteins / biosynthesis
  • Recombinant Fusion Proteins / chemistry
  • Substrate Specificity
  • Thrombophilia / genetics*
  • Transfection
  • Venous Thrombosis / etiology*
  • Venous Thrombosis / genetics

Substances

  • Recombinant Fusion Proteins
  • Antithrombin III